Merck Withdrawing From China’s Human Growth Hormone Market
This article was originally published in PharmAsia News
Executive Summary
Merck has decided to progressively pull human hormone injection Saizen (somatropin injection)from the Chinese market, according to one member of the staff, because of the drug’s dosage form changes worldwide and the difficulty in selling alternative non-powder forms in China.